Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of other drugs on Relutrigine

1 evidence topic · 1 source

Ciprofloxacin coadministration: increased relutrigine exposure

“relutrigine exposure (AUC ~31%)” (opens the source at this quote in a new tab)